Connect with us

Health

Two weeks into the Omicron outbreak: Where to from here?

A little more than two weeks since omicron’s discovery a lot has been learned about the latest coronavirus variant. A lot remains to be discovered.

Early data from South Africa, the epicenter so far, shows that the virus appears to spread far faster than earlier strains but also doesn’t appear to be causing severe disease.

Nothing is definitive yet, so the world is still somewhat in the dark. With omicron cases doubling every few days in the UK, policymakers and investors are grasping at any clues; the spread in Britain could be a harbinger of things to come across Europe and the US.

For more coronavirus news, visit our dedicated page.

Health officials had been moving toward the end of year with a little hope that the Covid era was shifting into a newer, more manageable phase.

But now it’s not clear yet if 2022 will succeed where 2021 has been defeated: suppress the spread of the virus enough to stop the rolling infection waves and finally end social restrictions.

Initial lab studies indicate omicron is much more transmissible than even delta, the strain that spread rapidly across the globe, filling hospitals and boosting death rates. They also show that it can infect the vaccinated or those who have already been ill with Covid-19.

What’s not known yet is how it developed, and whether it will cause more severe disease in countries with older populations than South Africa. Also unclear is whether it can out-compete delta in places where that version is dominant now, such as Europe and the US. New cases in South Africa, following a severe delta-led third wave, were negligible for weeks before omicron’s unwelcome emergence.

Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota, said this week that information so far points to a less severe mutation.

“The big challenge we’re going to have is confirming that over the next two weeks, he said on his Osterhom Update podcast. “From there, then we can figure out what does it mean in terms of the next leg of the pandemic for the world.

This is what we know so far:

How fast is omicron spreading?

In Gauteng, where South Africa’s outbreak is currently centered, the reproduction rate — how fast the virus spreads — is over 3. That’s the highest it’s been and means that every infected person on average infects three more.

Cases in South Africa are rising at a near-record pace, and the rate of increase has outstripped South Africa’s three earlier waves.

Omicron is 4.2 times more transmissible than delta, according to a study in Japan.

The UK says the new strain is growing much faster than delta, and it expects omicron to become the dominant variant by the middle of December, accounting for more than half of new cases. On Friday, the UK reported almost 58,200 Covid cases overall.

How severe are infections?

With the outbreak just a few weeks old it’s too early to tell definitively, but doctors have reported patients with fatigue and headaches and little more. That’s a big contrast to delta’s racing pulse rates and respiratory problems.

South Africa’s three biggest private hospital operators say cases are much milder than in earlier waves. There are few people on oxygen or ventilators and only a slight uptick in deaths.

Currently there are about 5,000 people with Covid in South African hospitals, a quarter of the peaks seen in the previous two waves.

Does it affect children differently from earlier variants?

Initial hospital admissions in South Africa saw a higher number of children under the age of 5 than previously.

Still, most only stay in hospital for a short time, and Health Minister Joe Phaahla says there are no reports of respiratory complications.

Do vaccines work?

Yes and no.

The Africa Health Resource Institute was the first to isolate the virus and test it against Pfizer Inc.’s shot. Omicron is able to largely, but not completely, evade the antibodies generated in response to the inoculation, the research showed. Pfizer’s own study backed that up.

The U.K. said Friday that two shots from AstraZeneca Plc or the Pfizer-BioNTech SE partnership provided much less protection against symptomatic infection with omicron, compared with the delta strain. But a booster lifted that to 70 percent to 75 percent in the early days after the shot, according to preliminary data from a small study.

Data from South African hospitals in the municipal area of Tshwane presented on Dec. 3 showed that 68 percent of coronavirus hospital admissions were in people under 40. That compares with individuals over 50 accounting for 66.1 percent of hospitalizations during the first weeks of the third wave. South Africans over 60 are about twice as likely to have been vaccinated than those under 34.

Where did it come from?

There are three theories.

The first is the virus mutated in someone who was immunosuppressed and harbored the pathogen for a long time, allowing it to change and then infect others. South Africa has 8.2 million people carrying HIV, which causes the immune system disease AIDS.

The second is that the coronavirus crossed back into an animal, mutated, and then re-infected a human.

The third is that it developed by circulating somewhere with little genetic sequencing and not much access to healthcare. It was then picked up in South Africa, where sequencing of samples is comparatively common. Some of the world’s weakest health systems are in Africa.

So where to from here?

Depends who you listen to.

Richard Friedland, the chief executive officer of South Africa’s biggest private hospital group, Netcare Ltd. is optimistic.

“I actually think there is a silver lining here and this may signal the end of Covid-19, with it attenuating itself to such an extent that it’s highly contagious, but doesn’t cause severe disease, he said. “It’s early days, but I’m less panicked. It feels different to me on the ground.

The World Health Organization is remaining cautious for now given so many unknowns, and the concern that any variant is a risk.

“If they’re allowed to spread unchecked, even though they’re not individually more virulent or more lethal, they generate more cases, put pressure on the health system and more people die, said Mike Ryan, executive director of the WHO emergencies program. “We should hope for the best outcome, but in this particular case, hope is not a strategy. We need to be very careful on making any final determinations on severity.

Read more:

South African doctors see signs Omicron is milder than Delta

Omicron may pose higher reinfection risk but could be milder than Delta: WHO

Pfizer vaccine shot provides partial Omicron shield in early study

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Children’s Hospital Los Angeles Named Among Top 10 Children’s Hospitals in the United States 16 Years in a Row

As a leader in pediatric academic medicine, Children’s Hospital Los Angeles (CHLA) has continued to fulfill its mission by making discoveries and advances to enhance health and save lives. Today, Children’s
Hospital Los Angeles was recognized among the top 10 pediatric hospitals in the United
States, according to U.S. News & World Report, which has announced the 2024-25
edition of its annual Best Children’s Hospitals rankings.
The privilege of earning a place on U.S. News Honor Roll of Best Children’s
Hospitals has been conferred upon CHLA 16 years and counting, since the magazine
created the list. Additionally, CHLA retained its No. 1 children’s hospital ranking in U.S.
News’ separate regional survey of Pacific Rim pediatric hospitals, tying with two others
in the region. Children’s Hospital Los Angeles also tied for No. 1 in California and is the
No. 1 pediatric provider in Los Angeles. For the 2024-25 survey, U.S. News did not
publish ordinal rankings for the 10 hospitals that made the Honor Roll. All 10 are
considered equally top tier.
“Being recognized as one of the top children’s hospitals in the country demonstrates our
unwavering commitment and excellence in pediatric healthcare,” says CHLA President
and Chief Executive Officer Paul S. Viviano. “We are committed to enhancing health,
saving lives and providing the best care for children, teens, young adults and the
families we serve. Our dedicated team of doctors, nurses, and staff, all contribute to
helping us put our patients first and are the reason this achievement continues to be
possible.”
U.S. News & World Report also ranked hospitals in 11 individual subspecialties, and
CHLA was ranked in all of these. CHLA earned top-10 recognition in five of the
specialties: Cancer (6), Endocrinology (6), Gastroenterology & GI
Surgery (6), Orthopedics (4) and Urology (4). In all, CHLA earned national recognition
in all 11 specialty areas, including: Cardiology (12), Nephrology
(16), Neurology & Neurosurgery (15), Neonatology (21) and Pulmonology (11).
Children’s Hospital Los Angeles was also honored in U.S. News & World Report’s
newest category—Pediatric and Adolescent Behavioral Health—which was added in
response to the national mental health crisis affecting children, adolescents and young
adults. For this first year, the publication identified CHLA among a group of 50 pediatric

hospitals providing the highest quality, compassionate care for youth coping with
behavioral and emotional challenges. CHLA’s Behavioral Health Institute provides
seamless care of Psychiatry, Developmental-Behavioral Pediatrics, Psychology, and
Social Work services, including for specific conditions such as autism spectrum disorder
and other developmental disabilities.
“Being ranked as one of the nation’s top hospitals in the country reflects our ability to
offer and provide specialized pediatric services, including world class care for complex
cases – rare and chronic conditions treated by multi-disciplinarian teams of pediatric
clinicians. This ability to care for these unique children is what sets CHLA apart from
other hospitals,” says CHLA Chief Medical Officer James Stein, MD, MSc. “At CHLA
we deliver more pediatric care for patients with complex conditions than any other
hospital in California. We are constantly advancing our practices and research to
provide solutions that continue to save lives.”
Children’s Hospital Los Angeles has more than 8,000 team members—including nearly
1,000 pediatric specialist physicians. The hospital performs nearly 16,000 surgeries and
conducts more than 723,000 patient visits each year. As a pediatric academic medical
center, CHLA delivers world-class medical care; conducts groundbreaking scientific
research to develop new treatments and new cures for childhood diseases at The
Saban Research Institute of CHLA; and operates one of the largest pediatric training
programs in the country for physicians, nurses and other specialists.
CHLA is one of the nation’s premier pediatric institutions with services and outcomes for
rare and complex conditions among the best in the world. It has treated patients from
more than 90 countries and has a dedicated Center for Global Health to support the
unique needs of international patients and families traveling to CHLA for specialty and
complex care needs. International patients and families can contact the Center for
Global Health at internationalpatientreferrals@chla.usc.edu.
“Our Center for Global Health supports the unique needs of international patients with a
single point-of-contact to make it easy for them and their families to access and
navigate all aspects of care,” said Yadira Torres, Executive Director of the Global Health
Program at CHLA. “We also make it a priority to be culturally diverse, offering services
in over 34 languages, so families can easily and effectively communicate with our
doctors, nurses and medical staff.”
Each year, U.S. News & World Report and research firm RTI International develop the
Best Children’s Hospital list. For 2024-25, The Best Hospitals specialty rankings
assessed nearly 200 pediatric hospitals—including freestanding institutions like CHLA,
children’s hospitals that are part of a larger health system, and specialty pediatric
centers. Each was scored across hundreds of benchmarks, including quality and safety
performance; patient outcomes; peer recognition; research; technology; commitment to
care that is diverse, equitable and inclusive; certifications; third-party awards; and other
data points provided by each hospital.

Continue Reading

Health

Tamkeen’s support for “Amana Healthcare” will provide hundreds of job opportunities for local talent in the healthcare sector

– Collaboration will generate job opportunities for local talent and support the growth of
Bahrain’s healthcare sector
– Recruitment Day on 12 October in Manama with vacancies for doctors, nurses, physical
therapists, nutritionists, and administrative staff.
– Amana Healthcare’s new facility in Al Jasra will replicate the successful patient care
model of M42’s Amana Healthcare in the UA

The Labour Fund “Tamkeen”has announced its collaboration with Amana Healthcare to attract top talent to Bahrain to deliver specialized rehabilitation and long-term care services for individuals with complex medical needs. This collaboration will create promising job opportunities for Bahrainis and strengthen
the Kingdom’s position as a growing hub for specialized healthcare services.
As part of this initiative, a Recruitment Day will take place on 12 October 2024 in Manama to
recruit the Kingdom’s most skilled local professionals to join Amana Healthcare’s team.
Qualified candidates may register online by 8 October at amanahealthcarebh.com for various
positions including doctors, nurses, physical therapists, nutritionists, and administrative staff.
Tamkeen’s support for Amana Healthcare is aligned with its strategic priorities focused on
economic impact under three pillars: increasing economic participation through employment,
career development opportunities for local talent in the private sector, and supporting private
sector enterprises to be the engine of economic growth.
Commenting on the collaboration, Her Excellency Ms. Maha Abdulhameed Mofeez, Chief
Executive of Tamkeen, said: “Tamkeen’s support for Amana Healthcare is a continuation of our
ongoing efforts to support the growing healthcare sector, which currently employs more than
15,800 Bahrainis across various roles and specialties. We are proud to collaborate with Amana
Healthcare for its prominent role in providing integrated services and improving the quality of
healthcare in line with the highest global standards.”

Amana Healthcare, part of the M42 group, an Abu Dhabi-based tech-enabled global health
powerhouse, will launch the new specialized facility in partnership with Mumtalakat in 2025.
Amana Healthcare features state-of-the-art facilities and aims to reduce the pressure on
hospitals caused by long-term medical patients.
Dr. Mohamed AlSaati, Acting CEO of M42 Bahrain and CEO of Amana Healthcare in Bahrain
highlighted that bringing M42’s world-class tried and tested model for complex long-term and
post-acute rehabilitation services to Bahrain for the first time, will positively impact local
communities and create highly skilled jobs for Bahrainis. He said: “We’re committed to
enhancing and transforming the healthcare infrastructure in Bahrain by hiring, training, and
developing the very best Bahraini talent, including nurses, doctors, technicians, and support
staff.”
It is worth mentioning that Tamkeen has previously announced the launch of the largest
support bundle to train and employ national talent in the healthcare sector in collaboration
with the Supreme Council of Health, aimed at developing and training more than 700 Bahraini
professionals in the healthcare sector. This is part of Tamkeen’s mandate to make Bahrainis the
first choice for employment while also supporting private sector enterprises as the main driver
of economic growth in the kingdom.

 

Continue Reading

Health

Boehringer Ingelheim Launches Broadest Spectrum Parasiticide for Cats in the UAE

– The solution combines three medications delivering the broadest spectrum of protection
against internal and external parasites in cats.
– The solution is safe for cats from eight weeks of age in addition to pregnant and lactating
cats.
– The solution aims to ensure convenience for veterinarians, while ensuring cat owner
compliance and broad-spectrum protection for cats against parasite

Boehringer Ingelheim has launched a breakthrough monthly parasiticide solution for cats in the UAE, to ensure convenient and comprehensive protection for cats and cat owners.
The solution combines esafoxolaner for fleas and ticks, and eprinomectin and praziquantel for internal
parasites, delivering a broad-spectrum of protection against fleas, ticks, mites, worms, and other
parasites. The solution is safe for cats from eight weeks of age in addition to pregnant and lactating cats
and provides a one and done solution, ensuring convenience for veterinarians, cat owners and cats alike.
During the launch event, which took place on 30 September in the presence of over 100 veterinarians
from the UAE and beyond, Dr. Remo Lobetti, President of the European College of Veterinary
Internal Medicine and a renowned expert in small animal medicine, spoke about the significant health
risks that parasites pose to cats. He emphasized the importance of comprehensive protection, stating,
“Feline parasites can cause a variety of health issues, ranging from mild skin irritations to serious
diseases that affect multiple organs. While fleas are the most common parasite in cats, there are many
other internal parasites that go unnoticed but pose severe health risks. The new solution by Boehringer
Ingelheim is a groundbreaking solution addressing not just the visible signs but also the hidden threats,
offering cats all-round protection. It’s an innovative step forward in parasite control, providing much
needed peace of mind for veterinarians and cat owners.”
Gurkan Ulusoy, Head of Animal Health, Near East and UAE, at Boehringer Ingelheim, said,
“Contrary to popular belief, parasites are not limited to cats allowed outdoors. They can be found in dirt,
indoor and outdoor plants, shoes, and other animals. One of the main challenges in treating cats,
particularly here in the UAE, is ensuring that the treatment process is stress-free and convenient for both
pets and time-pressed owners. With the hot climate in the region, cats face especially high risk exposure
to a range of parasites year-round, not just during specific seasons. Boehringer Ingelheim has addressed
these concerns by offering a topical application that is easy to administer and provides comprehensive
protection. The convenience of the solution has the potential to create better compliance from pet owners,
ensuring domesticated cats remain protected”
The new solution by Boehringer Ingelheim is available by veterinarian prescription in the UAE, providing a
trusted solution for all cat owners to protect their pets against parasites. With its advanced formula and
convenient administration, the product represents a significant advancement in feline healthcare. Cat
owners are encouraged to consult their trusted veterinarians for more information on the various parasites
and their treatment.
The launch of the new solution is testament to Boehringer Ingelheim’s commitment to animal health
through detection, prevention, and treatment and adds to the company’s wide-ranging animal health
portfolio containing some of the most respected and widely used vaccines, parasiticides and therapeutics products. Over the past several decades, the global pharmaceutical leader has transformed the lives of animals and the people who care for them to help ensure no animal suffers from a preventable disease.

 

Continue Reading

Trending